Analyst Meeting Presentation PDF
Preview Analyst Meeting Presentation
Analyst Meeting May 23, 2016 AAddvvaanncciinngg LLiivveess aanndd tthhee DDeelliivveerryy ooff HHeeaalltthh CCaarree™™ Forward Looking Statements This presentation contains some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, including multi-year projections of revenue, earnings per share and other financial measures. The accuracy of these statements are necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate," "estimate," "expect," "project," "intend," "forecast," "plan” and other words of similar meaning. Many factors may cause actual results to differ materially from anticipated results, including product development, sales efforts, income tax matters, the outcome of contingencies such as legal proceedings, the uncertainty of loss reserve estimates, share repurchases, acquisitions, foreign exchange and other economic, business competitive and regulatory factors. Please refer to the Cautionary Statement regarding forward-looking information in the company’s most recent 10-Q and the information under the caption “risk factors” in the company’s 2015 10-K, including disclosure of the factors that could cause actual results to differ materially from those expressed or implied. This presentation may also include references to certain non-GAAP measures, which management believes provide an additional and meaningful assessment of the core operating performance of the company and its individual product categories. Reconciliations of non-GAAP measures to the most comparable GAAP measures with respect to the company's historical financial results are provided in Bard's earnings press releases and on the company's website at www.crbard.com. All information that is not historical is given only as of May 23, 2016 and the company undertakes no responsibility to update any information. Unless otherwise noted, all comparisons are to the prior-year period. Advancing Lives and the Delivery of Health Care™ Tim Ring Chairman & CEO AAddvvaanncciinngg LLiivveess aanndd tthhee DDeelliivveerryy ooff HHeeaalltthh CCaarree™™ Agenda Tim Ring Tim Collins Chairman & CEO Group President Urology, Worldwide Operations, Canada, Europe, John Weiland Middle East and Africa President & COO John DeFord, PhD Jim Beasley Senior Vice President Group President Science, Technology and Clinical Affairs Peripheral Vascular, Lutonix, Japan and Latin America Chris Holland John Groetelaars Senior Vice President & CFO Group President Oncology, Surgical Specialties, China, Asia and Australia/New Zealand Advancing Lives and the Delivery of Health Care™ Key Takeaway The Sustainability of Above-Market Performance Advancing Lives and the Delivery of Health Care™ The Disclosed Pipeline is a Small Part of the Story • 150+ ideas being pursued (pre-R&D pipeline) • 100+ projects are in the R&D pipeline • We are talking about 35 projects today Advancing Lives and the Delivery of Health Care™ Building a Sustainable Engine § Product § Focus on Results People Leadership and Execution (selective where Process we compete) § Relatively Small, yet Balanced and § Clinical Geography Diversified Differentiation Products § Low ASPs § Focus on Quality § Financially and § Decentralized and Operationally Close to Customer Stringent Advancing Lives and the Delivery of Health Care™ Quality of Earnings Company Cash Conversion Sustainability Overall Ranking Prior Ranking C. R. Bard 2 1 1 2 Johnson & Johnson 10 5 2 9 Edwards 1 20 3 3 BD 8 9 4 5 Intuitive 6 18 5 6 Hill-Ro 13 6 4 Cash Conversion (5 year Free Cash Flow/Adjusted Net Income) 140% Median 120% 87% 100% 80% 60% 40% 20% BCR Advancing Lives and the Delivery of Health Care™ Source: Morgan Stanley Research May 13, 2016 Consistent Returns Return on Net Operating Assets (including Amortization) 35% 30% 25% 20% RNOA 15% Median 10.9% 10% 5% 0% BCR Advancing Lives and the Delivery of Health Care™ Source: Morgan Stanley Research May 16, 2016 Building a Sustainable Engine § Product § Focus on Results People Leadership and Execution (selective where Process we compete) § Relatively Small, yet Balanced and § Clinical Geography Diversified Differentiation Products § Low ASPs § Focus on Quality § Financially and § Decentralized and Operationally Close to Customer Stringent Advancing Lives and the Delivery of Health Care™
Description:The list of books you might like
